Climb Bio, Inc. CLYM
Set alert
9.74 USD -0.51 -4.98%
At close · Nov 2
9.74 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
9.69 Day range 10.44
1.64 52-week range 18.33
- YTD
- +143.50%
- 1 year
- +375.12%
- Open
- 10.25
- Prev close
- 10.25
- Mkt cap
- 559.43M
- Vol
- 1.15M
- Avg vol
- 1.41M
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.69
- High
- 10.44
- Forward P/E
- -16.92
- Beta
- 0.08
- Short ratio
- 5.77
- Inst. own
- 105.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.42
- 200-d avg
- 8.11
- 1y target
- 22.86
5Y chart
Events in this range
- Aug 12, 2025Earnings: -0.13; estimate -0.19; surprise 31.58%
- Nov 6, 2025Earnings: -0.19; estimate -0.16; surprise -18.75%
- Mar 5, 2026Earnings: -0.26; estimate -0.2; surprise -30%
- May 7, 2026Earnings: -0.2; estimate -0.26; surprise 23.08%
- Jun 12, 2026Rating: Wedbush · Outperform → Outperform
- Jun 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 27, 2026Rating: Wedbush · Outperform → Outperform
- Aug 6, 2026Earnings: -0.18; estimate -0.20931; surprise 14%
- Aug 7, 2026Rating: Truist Securities · Buy → Buy
- Aug 19, 2026Rating: Wedbush · Outperform → Outperform
- Aug 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 5, 2026Earnings: —; estimate -0.21; surprise —%
Signals (79)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Apr 6, 2026 | 7 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Jan 5, 2026 | 10 months ago |
| RSI: Overbought | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| RSI: Oversold | May 5, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bullish | Sep 2, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| RSI: Overbought | Jun 3, 2024 | 2 years ago |
| RSI: Overbought | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Apr 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 29, 2024 | 2 years ago |
| SMA: Bullish | Dec 25, 2023 | 2 years ago |
| SMA: Bearish | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| SMA: Bullish | Sep 11, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 14, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 31, 2023 | 3 years ago |
| SMA: Bearish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 3, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Mar 20, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Sep 12, 2022 | 4 years ago |
| RSI: Oversold | Aug 1, 2022 | 4 years ago |
| RSI: Oversold | Jul 18, 2022 | 4 years ago |
| RSI: Oversold | Jun 27, 2022 | 4 years ago |
| RSI: Oversold | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Mar 21, 2022 | 4 years ago |
| SMA: Bullish | Mar 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 760.15M
- Trailing P/E
- 0.00
- Forward P/E
- -16.92
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.28
- EPS (TTM)
- -0.82
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -33.99M
- Total cash
- 183.12M
- Total debt
- 1.31M
- Return on equity
- -27.10%
- Shares outstanding
- 57.44M
- Short % of float
- 17.28%
- 50-day average
- 13.42
- 200-day average
- 8.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 22.86 +134.7% upside
Now 9.74
- Target (low)
- 18.00
- Target (mean)
- 22.86
- Target (high)
- 35.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.195.
Financials — quick view
CLYM Revenue — quarterly 0
CLYM Net income — quarterly -13.50M
CLYM EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.21 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.20931 | -0.18 | +0.03 | +14.00% |
| May 7, 2026 | Mar 31, 2026 | -0.26 | -0.20 | +0.06 | +23.08% |
| Mar 5, 2026 | Dec 31, 2025 | -0.20 | -0.26 | -0.06 | -30.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.16 | -0.19 | -0.03 | -18.75% |
| Aug 12, 2025 | Jun 30, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jul 27, 2026 | Wedbush | main | Outperform | Outperform |
| Jun 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | Wedbush | reit | Outperform | Outperform |
About Climb Bio, Inc.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- climbbio.com
News
- Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
- Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN
- Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
- Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
- Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
- Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
- Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
- Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
- Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Your note
Sign in to keep a note on CLYM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN AOIFE M | Chief Executive Officer | Sale | Jun 28, 2026 | 87,731 |
| PIMBLETT EMILY | Officer | Sale | Jun 19, 2025 | 18,888 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 4, 2026 | 0 |
| THOMAS STEPHEN BASIL | Director | Sale | Feb 25, 2026 | 154,657 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 19.68% | 11,300,939 | 201.61M | Jun 29, 2026 |
| FMR, LLC | 11.82% | 6,790,364 | 121.14M | Jun 29, 2026 |
| UBS Group AG | 5.93% | 3,404,866 | 60.74M | Jun 29, 2026 |
| Braidwell LP | 4.87% | 2,797,375 | 49.91M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.36% | 2,506,000 | 44.71M | Jun 29, 2026 |
| Blackrock Inc. | 4.10% | 2,354,872 | 42.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 2.56% | 1,468,417 | 26.20M | Mar 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.74% | 996,857 | 17.78M | May 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.73% | 996,400 | 17.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.60% | 920,068 | 16.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.49% | 854,986 | 15.25M | Mar 30, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 0.94% | 537,698 | 9.59M | May 30, 2026 |